ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
NCT02362035 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 161
Last updated 2026-05-13
Summary
This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.
Conditions
- Follicular Lymphoma (FL)
- CLL
- Small Lymphocytic Lymphoma (SLL)
- Richter's Syndrome
- Mantle Cell Lymphoma (MCL)
- Indolent Non Hodgkin Lymphoma
- Waldenström Macroglobulinemia
- Multiple Myeloma
- Hodgkin Lymphoma
- Burkitt Lymphoma
- Marginal Zone Lymphomas
- Mediastinal Large B Cell Lymphoma
- Hairy Cell Leukemia
Interventions
- DRUG
-
Orally Administered (PO)
- DRUG
-
Intravenous Administered (IV)
Sponsors & Collaborators
- collaborator INDUSTRY
-
Acerta Pharma BV
lead INDUSTRY
Principal Investigators
-
AstraZeneca Clinical Study Information Center · 1-877-240-9479 - [email protected]
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-02-20
- Primary Completion
- 2020-07-14
- Completion
- 2025-10-27
Countries
- United States
Study Locations
More Related Trials
-
A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy
NCT02717611 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
NCT02337829 ·Status: COMPLETED ·Phase: PHASE2
-
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT03516617 ·Status: RECRUITING ·Phase: PHASE2
-
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
NCT02296918 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
NCT04402138 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
NCT03836261 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
NCT04722172 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970318 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
NCT02269085 ·Status: TERMINATED ·Phase: PHASE1
-
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
NCT02475681 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
NCT00098826 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
NCT03153202 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
NCT04505254 ·Status: RECRUITING ·Phase: PHASE2
-
A Study Of The Selective PKC-β Inhibitor MS- 553
NCT03492125 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT01670084 ·Status: WITHDRAWN ·Phase: PHASE2
-
Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia
NCT03441048 ·Status: COMPLETED ·Phase: PHASE1
-
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05388006 ·Status: RECRUITING ·Phase: PHASE2
-
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
NCT03263572 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05057494 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia
NCT03512405 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
NCT06308588 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
NCT05336812 ·Status: RECRUITING ·Phase: PHASE2
-
Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia
NCT01294618 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
NCT02242942 ·Status: COMPLETED ·Phase: PHASE3
-
PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy
NCT00335868 ·Status: UNKNOWN ·Phase: PHASE2